SEC Company Response from Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247) — Jul 7, 2005
Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Date: July 7, 2005 · CIK: 0000887247 · Accession: 0001047469-05-019028
AI Filing Summary & Sentiment
File numbers found in text: 333-125787
Letter
Cellegy Pharmaceuticals, Inc. 1000 Marina Boulevard, Suite 300
Brisbane, CA 94005
July 7,
VIA EDGAR
Securities and Exchange Commission
Judiciary Plaza
450 Fifth Street, N.W.
Washington, D.C. 20549-0306
Attention: Jeffrey P. Riedler, Assistant Director
Re:CELLEGY PHARMACEUTICALS, INC.
REGISTRATION STATEMENT ON FORM S-3 (No. 333-125787)
ACCELERATION REQUEST
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Cellegy Pharmaceuticals, Inc. (the "Company") hereby requests that the effective date of its Registration Statement on Form S-3 (File No. 333-125787) be accelerated so that the same will become effective at 9:00 a.m., Washington, D.C. Time, on Friday, July 8, 2005, or as soon thereafter as practicable.
The Company hereby acknowledges the following:
(i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yours truly,
CELLEGY PHARMACEUTICALS, INC
By:
/s/ ROBERT J. CASO Robert J. Caso, Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
Cellegy Pharmaceuticals, Inc.
1000 Marina Boulevard, Suite 300
Brisbane, CA 94005
July 7,
2005
VIA EDGAR
Securities
and Exchange Commission
Judiciary Plaza
450 Fifth Street, N.W.
Washington, D.C. 20549-0306
Attention: Jeffrey
P. Riedler, Assistant Director
Re:CELLEGY PHARMACEUTICALS, INC.
REGISTRATION STATEMENT ON FORM S-3 (No. 333-125787)
ACCELERATION REQUEST
Ladies and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Cellegy Pharmaceuticals, Inc. (the "Company") hereby requests that the effective
date of its Registration Statement on Form S-3 (File No. 333-125787) be accelerated so that the
same will become effective at 9:00 a.m., Washington, D.C. Time, on Friday, July 8, 2005, or as soon thereafter as practicable.
The
Company hereby acknowledges the following:
(i) should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action
with respect to the filing;
(ii) the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full
responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) the
Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yours truly,
CELLEGY PHARMACEUTICALS, INC
By:
/s/ ROBERT J. CASO Robert J. Caso, Chief Financial Officer